Overview
Nilandron is approved by the U.S. Food and Drug Administration (FDA) for the treatment of metastatic (advanced) prostate cancer. It is prescribed for use in combination with surgical castration (removal of the testicles) to reduce androgen (a type of sex hormone) levels that fuel cancer growth. Nilandron is also known by its drug name, nilutamide.

Nilandron is a nonsteroidal antiandrogen. It works by blocking the action of androgens like testosterone at the receptor level. This helps reduce or stop the growth of prostate cancer cells that depend on these hormones.

How do I take it?
Prescribing information states that Nilandron is taken by mouth. Treatment should begin on the same day or the day after surgical castration. A higher starting dose is taken once daily for the first 30 days, followed by a lower dose taken once daily. The tablets can be taken with or without food. The drug should be taken exactly as prescribed by a healthcare provider.

Side effects
Common side effects of Nilandron include hot flushes, nausea, constipation, dizziness, difficulty adapting to changes in light (especially from light to dark), impaired vision, fatigue, high blood pressure, increased liver enzymes, shortness of breath, urinary tract infection, and muscle or bone pain.

Rare but serious side effects may include interstitial pneumonitis (lung inflammation), which can cause cough, chest pain, fever, and breathing difficulty; severe liver injury including hepatitis and liver failure; and a rare risk of aplastic anemia (a serious blood disorder). Some people may experience alcohol intolerance (flushing, low blood pressure, and malaise). Visual disturbances may not resolve during treatment, and people should be cautious when driving at night or in tunnels.

For more information about this treatment, visit:
Label: Nilandron — Nilutamide Tablet — DailyMed